NEW YORK–(COMMERCIAL THREAD) – Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to two discussion webcasts with Pfizer executives at two upcoming healthcare conferences.
Frank D’Amelio, CFO, Executive Vice President, Global Sourcing, to Hold Fireside Conversation at Morgan Stanley 19e Annual Global Healthcare Conference Tuesday, September 14, 2021 at 10:15 a.m. Eastern Daylight Time.
Angela Hwang, President of Pfizer Biopharmaceuticals Group, will hold a fireside chat at the BofA Global Healthcare 2021 conference on Wednesday, September 15, 2021 at 11:45 a.m. Eastern Daylight Time.
The transcript and webcast of the discussion will be available on our website at www.pfizer.com/investisseurs within 24 hours of the end of the live chat and will be accessible for at least 90 days.
About Pfizer: Advances That Change Patients’ Lives
At Pfizer, we apply science and our global resources to provide people with therapies that significantly extend and improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health products, including innovative drugs and vaccines. Every day, Pfizer colleagues work in developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most dreaded diseases of our time. In line with our responsibility as one of the world’s leading innovative biopharmaceutical companies, we collaborate with healthcare providers, governments and local communities to support and expand access to reliable and affordable healthcare in the whole world. For more than 170 years, we’ve worked to make a difference for all those who rely on us. We regularly post information that may be important to investors on our website at www.Pfizer.com. In addition, to find out more, visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, Youtube and like us on Facebook at Facebook.com/Pfizer.
Disclosure Notice: Webcasting may include forward-looking statements regarding, among other things, our anticipated operational and financial performance, reorganizations, business plans and prospects; expectations for our product portfolio, in-line products and product candidates, including planned regulatory submissions, data readings, study starts, approvals, clinical trial results and other developing data that become available, contribution to revenue, growth, performance, timing of exclusivity and potential benefits; strategic reviews; capital allocation objectives; dividends and share buybacks; the plans and outlook for our acquisitions, divestitures and other business development activities, and our ability to successfully capitalize on these opportunities; manufacture and supply of products; our efforts to respond to COVID-19, including our development of a vaccine to help prevent COVID-19 which are subject to substantial risks and uncertainties which could cause actual results to differ materially from those expressed or under – understood by such statements. A description of these risks and uncertainties can be found in Pfizer’s annual report on Form 10-K for the year ended December 31, 2020 and in its subsequent reports on Form 10-Q, including in sections thereof. entitled “Risk factors” and “Forward-looking information and factors that may affect future results â, as well as in its subsequent reports on Form 8-K, all filed with the United States Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.
Forward-looking statements made in the webcast speak only as of the original date of the webcast. Pfizer assumes no obligation to update any forward-looking statements contained in the webcast as a result of new information or future events or developments.